HOGA1 Antibody - BSA Free

Western Blot: HOGA1 Antibody - BSA Free [NBP3-06562] -

HOGA1 expression in ccRCC tissues and correlations to survival. (A) Volcano plot graph showing the differential expressed proteins in the quantitative analysis. The −log10 (p‐value) was plotted against the log2 (ratio T/N). N represented adjacent nontumour tissues. T represented tumour tissues. The upregulated proteins in ccRCC tissues were marked with red dots and the downregulated proteins in ccRCC tissues with green dots. (B) Relative HOGA1 expression was detected by IHC between ccRCC tumours and adjacent nontumour kidney tissues (n = 6, scale bars, 50 μm). (C) Protein levels of HOGA1 in ccRCC tumours and matched adjacent noncancer tissues were analysed by western blot (n = 6). (D) mRNA levels of HOGA1 in ccRCC tumours and matched adjacent noncancer tissues were analysed by RT‐PCR (n = 6). (E) The GEPIA database showed HOGA1 low expression in ccRCC compared to normal tissues (normal, n = 100; ccRCC, n = 523) cohorts. (F) Low‐level HOGA1 expression correlates with poor survival outcomes in ccRCC (high, n = 258; low, n = 258) cohorts based on survival analysis. (G) HOGA1 is downregulated with ccRCC grade increase based on the GEPIA database. *p < 0.05 and ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40100076), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: HOGA1 Antibody - BSA Free [NBP3-06562] -

HOGA1 inhibits cell proliferation and migration in ccRCC cells. (A) Western blot validated the expression of HOGA1 and HOGA1 siRNA transfection in 786‐O cells. (B‐C) CCK‐8 assay was performed to examine the effect of HOGA1 overexpression and HOGA1 knockdown on cell viability in 786‐O cells. (D) Wound‐healing assay determined the migratory distances of HOGA1 overexpression and control. Scale bars, 10 μm. (E) The effect of HOGA1 overexpression on cell migration and invasion was evaluated by transwell assay. Scale bars, 200 μm. (F) Wound‐healing assay determined the migratory distances of HOGA1 knockdown and control. Scale bars, 10 μm. (G) The effect of HOGA1 knockdown on cell migration and invasion was evaluated by transwell assay. Scale bars, 200 μm. *p < 0.05, **p < 0.01 and ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40100076), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: HOGA1 Antibody - BSA Free [NBP3-06562] -

HOGA1 suppresses ccRCC growth in vivo. (A) HOGA1 protein expression in CON or HOGA1‐OE ccRCC cells. (B) 786‐O cells stably expressing HOGA1 were injected subcutaneously into 5‐week‐old male NOD SCID mice (n = 5), and growth curves of subcutaneous tumours were drawn in NOD SCID mice (n = 5). (C) The tumour size in two groups was shown in NOD SCID mice (n = 5). (D) The tumour weight in CON and HOGA1 groups were shown (n = 5). (E) Immunohistochemistry of HOGA1 and Ki67 and quantification. Scale bar: 100 μm. (F) Effect of overexpression of HOGA1 on Wnt/ beta‐catenin signalling pathway in vivo. **p < 0.01, ***p < 0.001 and ****p < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40100076), licensed under a CC-BY license. Not internally tested by Novus Biologicals.